City of Hope scientists develop structure to broaden SCINTIX treatment utilizing a prostate cancer-specific animal radiotracer
HAYWARD, Calif., June 26, 2023–(BUSINESS WIRE)–RefleXion Medical, Inc., a healing oncology business, today revealed that outcomes of a potential investigator-initiated scientific imaging research study carried out on its X1 platform by City of Hope utilizing positron emission tomography (ANIMAL) existed on June 24 throughout an oral session at the Society of Nuclear Medicine and Medical Imaging (SNMMI) yearly conference in Chicago. The research study results act as the structure for assessing making use of RefleXion’s SCINTIX™ biology-guided radiotherapy with a prostate-specific animal radiotracer for managing external-beam radiotherapy shipment to prostate cancer growth targets. City of Hope, among the biggest cancer research study and treatment companies in the U.S., is amongst the very first in the country to adopt this brand-new radiotherapy innovation that has the possible to alter the method metastatic cancer clients are dealt with.
This news release includes multimedia. View the complete release here: https://www.businesswire.com/news/home/20230626297838/en/
The prostate-specific animal radiotracer, 18F-DCFPyL, signals passionate bone transition in a client with prostate cancer. (Image thanks to City of Hope)
Recently cleared by the U.S. Food and Drug Administration (FDA), SCINTIX innovation is the very first and just cancer treatment that utilizes each cancer’s distinct biology to autonomously figure out where to provide radiotherapy, second-by-second, throughout the real cancer treatment to shown strong growths of any phase. SCINTIX treatment utilizes signals produced by an animal radiotracer engaging with cancer cells to manage shipment of external-beam radiotherapy to growth targets.
The prostate-specific animal radiotracer utilized in the provided research study – 18F-DCFPyL (PyL) – binds to prostate-specific membrane antigen (PSMA), a protein that is revealed in substantially raised quantities by prostate cancer cells. Also just recently authorized by the FDA for identifying and staging prostate cancer, PyL can precisely and specifically identify growths in both the prostate and in other body locations where the cancer might have spread out or metastasized.
“It is well developed that PyL exceptionally finds growths present in clients with prostate cancer, however targeting and dealing with those growths can be challenging utilizing existing radiotherapy techniques,” said Jeffrey Wong, M.D., teacher of the Department of Radiation Oncology and the Department of Immunology and Theranostics at City of Hope, and primary detective of the RefleXion-supported PyL imaging research study. “SCINTIX treatment might conquer these barriers, and our research study results assistance continued expedition of leveraging PyL’s accuracy to broaden SCINTIX treatment to clients with prostate cancer.”
The potential PyL imaging research study developed that growths developing from prostate cancer might be envisioned on the RefleXion® X1 platform utilizing signals from PyL constant with PyL diagnostic imaging research studies, which SCINTIX treatment strategies might be created utilizing these information. PSMA-directed SCINTIX treatment strategies likewise satisfied traditional radiotherapy organ dosage restraints, recommending the capability to extra close-by organs and other healthy tissue from possibly harmful radiation. SCINTIX treatment is presently cleared for usage with 18F fludeoxyglucose (FDG), a typical animal radiotracer, to treat main and metastatic growths in the lung and bone.
“We eagerly anticipate providing FDG-directed SCINTIX treatment to our clients in the next numerous weeks,” said Terence Williams, M.D., Ph.D., teacher and chair of City of Hope’s Department of Radiation Oncology. “As early partners in assessing SCINTIX innovation, it is pleasing to see research study and scientific advancement efforts already advancing it towards another client population in excellent requirement of enhanced radiotherapy techniques utilizing the well-characterized advantages of PyL.”
The discussion entitled “A Prospective Pilot Study of the RefleXion X1 PET-CT Subsystem Imaging Performance with [18F]-DCFPyL PSMA in Patients with Prostate Cancer” belonged to oral session SS10 “Focus on Clinical Studies – New Insights.”
About RefleXion Medical
RefleXion is an independently held restorative oncology business found in Hayward, Calif., advertising SCINTIX biology-guided radiotherapy, an unique treatment that utilizes a single radiotracer injection to change cancer cells into real-time biological beacons to manage external-beam radiotherapy shipment to numerous growths. Granted Breakthrough Device classification for lung growths and De Novo marketing permission by the FDA, SCINTIX treatment is shown for usage in lung and bone growths developing from either main lung and bone cancers or arising from metastases by other main cancers. RefleXion has co-development and co-commercialization arrangements with Lantheus and Telix for their PSMA-targeted animal radiotracers as SCINTIX treatment bioguides for prostate cancer applications. The RefleXion X1 is likewise cleared for traditional image-guided radiotherapy for strong growths situated throughout the body.
View source variation on businesswire.com: https://www.businesswire.com/news/home/20230626297838/en/
Contacts
RefleXion
Amy Cook
[email protected]
925-200-2125
City of Hope
Katherine Ramirez
[email protected]
626-678-4163
